文献速递前列腺癌

非转移性前列腺癌患者诊断后补锌与前列腺癌生存的关系

Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer.
PubMed 文献 · J Urol · 2022-12-01

在卫生专业人员随访研究(1986-2019)的5788例非转移性前列腺癌男性中,前瞻性评估诊断后补锌与前列腺癌生存的关系。中位随访11年,记录527例致死性前列腺癌事件和3198例全因死亡。诊断后补锌与致死性前列腺癌风险呈提示性降低(HR 0.82,95%CI 0.60-1.13),与全因死亡显著降低相关(HR 0.84,95%CI 0.74-0.96);该反向关联主要见于每日补锌1-24 mg者。

要点

  • 诊断后补锌与全因死亡风险显著降低相关(HR 0.84,95%CI 0.74-0.96)。
  • 诊断后补锌与致死性前列腺癌风险呈提示性降低(HR 0.82,95%CI 0.60-1.13)。
  • 反向关联主要见于每日补锌1-24 mg者,更高剂量未见更低风险。

核心结论

  • 非转移性前列腺癌患者诊断后低剂量补锌与致死性前列腺癌和全因死亡风险降低相关。
  • 作者认为诊断后低剂量补锌对前列腺癌生存的潜在获益值得进一步研究。

研究设计与样本

  • 前瞻性评估卫生专业人员随访研究(1986-2019)中5788例非转移性前列腺癌男性的诊断后补锌情况。
  • 采用Cox回归模型估计致死性前列腺癌(远处转移或前列腺癌特异性死亡)和全因死亡的多变量风险比及95%置信区间。

主要发现

  • 中位随访11年,记录527例致死性前列腺癌事件和3198例全因死亡。
  • 15%的男性报告诊断后使用锌补充剂。
  • 与未使用者相比,诊断后补锌与致死性前列腺癌风险呈提示性降低相关(HR 0.82,95%CI 0.60-1.13),与全因死亡显著降低相关(HR 0.84,95%CI 0.74-0.96)。
  • 该反向关联主要见于诊断后每日补锌1-24 mg者(致死性前列腺癌:HR 0.55,95%CI 0.32-0.96;全因死亡:HR 0.77,95%CI 0.64-0.93),更高剂量未显示更低风险。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 作者认为诊断后低剂量补锌对前列腺癌生存的潜在获益值得进一步研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Biological and experimental evidence support restoration of normal zinc levels in malignant prostate cells as a promising prostate cancer treatment, yet the influence of zinc supplementation after diagnosis on prostate cancer survival in a human population is unknown. MATERIALS AND METHODS: We prospectively assessed post-diagnostic zinc supplementation in relation to prostate cancer survival among 5,788 men with nonmetastatic prostate cancer in the Health Professionals Follow-up Study (1986-2019). We used Cox regression models to estimate the multivariable hazard ratios and 95% confidence intervals of lethal prostate cancer (distant metastases or prostate cancer-specific death) and all-cause mortality according to post-diagnostic zinc supplement use and dosage. RESULTS: During a median follow-up of 11 years, we documented 527 lethal prostate cancer events and 3,198 all-cause deaths. Fifteen percent of men reported zinc supplement use post-diagnosis. Compared to nonusers, post-diagnostic zinc supplement use was associated suggestively with a lower risk of lethal prostate cancer (HR [95% CI], 0.82 [0.60-1.13]) and significantly with all-cause mortality (0.84 [0.74-0.96]). The inverse association was mostly observed among men who used post-diagnostic zinc supplements of 1-24 mg/d (lethal prostate cancer: 0.55 [0.32-0.96]; all-cause mortality: 0.77 [0.64-0.93]), while higher dosage did not show a lower risk. CONCLUSIONS: Post-diagnostic low-dose zinc supplement use among nonmetastatic prostate cancer patients was associated with lower risk of lethal prostate cancer and all-cause mortality. A potential benefit of low-dose post-diagnostic zinc supplement for prostate cancer survival merits further study.

来源:J Urol,查看原文。版权归原作者所有。

引用

  1. Zhang Y, Stopsack KH, Wu K, et al. Post-diagnostic Zinc Supplement Use and Prostate Cancer Survival Among Men With Nonmetastatic Prostate Cancer. J Urol. 2022. PMID: 36453265. doi:10.1097/JU.0000000000003080

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。